Vaccine Safety & Efficacy

The term "antibody adequacy" refers to an immunization's ability to provide the desired beneficial effects for those who have received it in a defined population when used in its ideal form. The potential risks of an adverse event following vaccination (AEFI) with that immunization must be weighed against the potential benefits of a successful immunization, such as improvement of wellbeing and prosperity, protection from illness and its physical, mental, and financial outcomes. The risk that a negative or unwanted outcome would occur, as well as the severity of the ensuing harm to the wellbeing of those who have received vaccinations in a defined population, after receiving an immunization in optimal usage conditions.

  • nfluenza Vaccines

  • Measles Vaccines

    Related Conference of Vaccine Safety & Efficacy

    February 27-28, 2025

    8th International Conference on Vaccines and Immunology

    Paris, France
    April 28-29, 2025

    2nd Global Summit on Vaccines & Emerging Diseases

    Bali, Indonesia
    July 28-29, 2025

    43rd Euro Global Summit and Expo on Vaccines & Vaccination

    Aix-en-Provence, France
    September 18-19, 2025

    7th World Congress on Vaccine and Immunology

    Amsterdam, Netherlands
    October 06-07, 2025

    37th Annual Congress on Vaccine and Clinical Trials

    Vancouver, Canada

    Vaccine Safety & Efficacy Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in